Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) – Equities research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Ventyx Biosciences in a research note issued on Monday, September 23rd. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($2.13) for the year, up from their prior forecast of ($2.14). HC Wainwright currently has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q4 2024 earnings at ($0.58) EPS, FY2025 earnings at ($2.91) EPS, FY2026 earnings at ($2.29) EPS, FY2027 earnings at ($1.97) EPS and FY2028 earnings at ($1.59) EPS.
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.12.
View Our Latest Report on VTYX
Ventyx Biosciences Stock Performance
Shares of VTYX stock opened at $2.31 on Thursday. The firm has a market capitalization of $163.25 million, a PE ratio of -0.71 and a beta of 0.37. Ventyx Biosciences has a 1 year low of $1.79 and a 1 year high of $36.19. The stock has a fifty day moving average of $2.24 and a two-hundred day moving average of $3.63.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Deerfield Management Company L.P. Series C lifted its position in shares of Ventyx Biosciences by 64.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after acquiring an additional 2,287,570 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Ventyx Biosciences in the first quarter valued at $17,435,000. Redmile Group LLC boosted its position in shares of Ventyx Biosciences by 944.4% in the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock worth $11,903,000 after buying an additional 1,956,923 shares during the period. Opaleye Management Inc. grew its holdings in shares of Ventyx Biosciences by 12.7% during the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock valued at $7,068,000 after buying an additional 145,000 shares in the last quarter. Finally, First Light Asset Management LLC purchased a new position in shares of Ventyx Biosciences during the first quarter valued at $3,437,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.
About Ventyx Biosciences
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Stories
- Five stocks we like better than Ventyx Biosciences
- Stock Analyst Ratings and Canadian Analyst Ratings
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Compound Interest and Why It Matters When Investing
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- How to Find Undervalued Stocks
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.